Kite Pharma names Paul Jenkinson CFO
May 23, 2016Research and Development, Sales and Marketing appointment, cfo, kite pharma
Kite Pharma (Nasdaq: KITE) has appointed Paul Jenkinson its chief financial officer. Jenkinson succeeds Cynthia Butitta, who will continue in her role as …
Novartis’ heart failure drug Entresto gets top US, EU recommendation
May 23, 2016Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation
Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …
China to cut prices of GSK, AstraZeneca drugs
May 23, 2016Sales and Marketing AstraZeneca, China, GSK, drug prices
Chinese health authorities have announced steps to cut the prices of three costly drugs in their latest attempt to reduce …
Weekly Movers: Valeant, Anacor, Regeneron…
May 23, 2016Manufacturing and Production, Research and Development, Sales and Marketing Acorda, Aduro Biotech, Anacor Pharma, Financial, MacroGenics, Merck, Regeneron Pharma, Valeant Pharma
The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …
Biotech firm fined $3.5 million for animal mistreatment
May 23, 2016Medical Communications, Sales and Marketing US department of agriculture, animal cruelty, animal mistreatment, antibody, santa cruz biotechnology, usda
A US-based biotechnology company has been fined $3.5 million by the US Department of Agriculture (USDA) for a case related …
Bayer offers $62 billion for Monsanto in all cash deal
May 23, 2016Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto
German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
EMA to review Pfizer’s meningococcal vaccine
May 20, 2016Research and Development, Sales and Marketing EMA, Pfizer, meningitis, meningococcal vaccine, trumenba
Pfizer (NYSE: PFE) has announced that the European Medicines Agency has accepting the marketing authorisation application for its meningococcal group …
MSF says staff member shot dead in Central African Republic; suspends activity in the area
May 20, 2016Medical Communications Central African republic, MSF
The medical aid charity Doctors without Borders (MSF) said it is suspending activities in the Central African Republic (CAR) following an …
Nice backs Novartis’ lung cancer drug
May 20, 2016NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
May 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …
UK regulators do not back Roche’s breast cancer drug
May 20, 2016Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation
The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …
Chugai partners with Osaka University in £62 million immunology collaboration
May 20, 2016Medical Communications, Research and Development Chugai, collaboration, immunology, osaka university
Chugai Pharmaceuticals (TOKYO: 4519) has announced a collaboration agreement with Osaka University in advanced immunology research worth up to £62 …
Celator receives FDA breakthrough therapy designation for leukaemia drug
May 20, 2016Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator
A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …
Urgent action needed on antimicrobial resistance, says government report
May 19, 2016Manufacturing and Production, Medical Communications, Research and Development ABPI, Lord Jim O'Neill, NICE, antimicrobial resistance
A new UK governmental report has warned that the global rise of antimicrobial resistance is set to worsen, with the …
Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal
May 19, 2016Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results
Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
May 19, 2016Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
Bayer makes bid for Monsanto
May 19, 2016Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover
Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
May 19, 2016Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
